TITLE:
Efficacy and Tolerance of Hydroxycarbamide with Adult Sickle Cell Patients in Mali: A Cohort of 157 Patients Followed for 60 Months
AUTHORS:
Boubacari Ali Touré, Mahamoud Mahamadou Koureichi, Diakalia Siaka Berthé, Moussa Coulibaly, Aissata Traoré, Mariam Kanta, Sekou Kéné, Yeya dit Sadio Sarro, Aldiouma Guindo
KEYWORDS:
Sickle Cell Disease, Hydroxycarbamide, Adult, Fetal Hemoglobin, Vaso-Occlusive Crises, Mali, Sub-Saharan Africa
JOURNAL NAME:
Open Journal of Epidemiology,
Vol.16 No.4,
November
18,
2026
ABSTRACT: Introduction: Hydroxycarbamide or Hydroxyurea (HU) remains the only treatment considered as a modifier of the course of sickle cell disease, although it does not cure the disease. Its efficacy has been established through randomized, blinded clinical trials. The objective of this study was to describe the evolution of hematological parameters and the frequency of vaso-occlusive crisis.Method: This was a single-center retrospective cohort study of 157 adult patients aged 18 years and older who received HU treatment between January 2010 and December 2020. Hematological parameters and the annual number of vaso-occlusive crises were recorded at baseline and then at 6, 12, 24, and 60 months. At each time point, the analysis was restricted to patients who actually reached this period of follow-up. Paired comparisons were performed using the Wilcoxon signed-rank test. Changes at 60 months are reported on the matched subgroup of patients contributing a value both at baseline and at 60 months, with 95% confidence intervals. Results: The median age at initiation was 29 years (IQR 23-37), and 89 patients (56.7%) were female. The SS phenotype represented 68.2% of the cohort. Eighty-four patients (53.5%) had completed at least 60 months of treatment at the time of data extraction. In this matched subgroup, fetal hemoglobin increased from 4.8 ± 2.5% to 14.4 ± 5.4% (n = 36; mean change +9.6 points, 95% CI 8.0 to 11.2), hemoglobin from 8.8 ± 2.4 to 10.5 ± 1.4 g/dL (n = 79; +1.6 g/dL, 95% CI 1.2 to 2.1) and Mean Corpuscular Volume (MCV) from 82.2 ± 7.4 to 102.8 ± 8.6 fL (n = 79; +20.6 fL, 95% CI 18.5 to 22.7). The leukocyte count decreased from 9995 ± 3240 to 7544 ± 2082/µL (n = 79). In the same 84 patients, the annual number of vaso-occlusive crises fell from 3.80 ± 3.00 before treatment to 0.44 ± 0.95, a reduction of 88.4% (95% CI 83.5 to 92.9), and the proportion of patients without any crisis rose from 22.6% to 75.0%. Thrombocytopenia was recorded in 9 patients (5.7%). Cutaneous manifestations were frequent (29.3%) and benign. Conclusion: In this Malian adult cohort, HU treatment was associated with a sustained improvement in most hematological parameters and with a substantial reduction in the number of vaso-occlusive crises. Total hemoglobin was the exception, remaining statistically unchanged in the SC/Sβ+ group. Tolerance was dominated by benign cutaneous effects and by mild to moderate thrombocytopenia.